OncRef

Clinical Trial: NCT02595944

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 3

Lead Sponsor:National Cancer Institute (NCI)
Information Provided By:National Cancer Institute (NCI)
Last Update Posted:2026-10-01

Study Overview

Brief Summary

This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Official Title

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Conditions

Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7

Intervention / Treatment

  • Procedure: Biospecimen Collection
  • Procedure: Computed Tomography
  • Procedure: Echocardiography Test
  • Biological: Nivolumab
  • Other: Observation Activity
  • Procedure: Positron Emission Tomography

Other Study ID Numbers

  • NCI-2015-01916
  • NCI-2015-01916
  • s16-02074
  • EA5142
  • EA5142
  • U10CA180820

Start Date (Actual)

2016-07-22

Primary Completion Date (Estimated)

2027-05-31

Study Completion Date (Estimated)

2027-05-31

Enrollment (Estimated)

903

Study Type

Interventional

Phase

Phase 3